Ucb SA 2010 AR2
The report highlights UCB's progress in 2010 towards becoming a patient-centric biopharmaceutical leader, focusing on severe diseases in immunology and the central nervous system. Financially, the company exceeded guidance with revenue reaching €3.2 billion and recurring EBITDA at €731 million, driven by the growth of its core products Cimzia, Vimpat, and Neupro. UCB invested €705 million in research and development, representing 22% of its revenue. On the sustainability front, UCB reported its Corporate Social Responsibility performance at a GRI application level of C+, verified by PwC, and achieved a 16% reduction in waste compared to 2009.
Company: Ucb SA
Sector: Manufacturing
Country: Belgium
Year: 2010
Type: AR2
Pages: 160
Back to company
Ucb SA
Annual Report
The report highlights UCB's progress in 2010 towards becoming a patient-centric biopharmaceutical leader, focusing on severe diseases in immunology and the central nervous system. Financially, the company exceeded guidance with revenue reaching €3.2 billion and recurring EBITDA at €731 million, driven by the growth of its core products Cimzia, Vimpat, and Neupro. UCB invested €705 million in research and development, representing 22% of its revenue. On the sustainability front, UCB reported its Corporate Social Responsibility performance at a GRI application level of C+, verified by PwC, and achieved a 16% reduction in waste compared to 2009.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2010
Reporting Period
Jan 1, 2010 - Dec 31, 2010
Fiscal Year
2010
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees